



**Telix Pharmaceuticals Limited**  
ACN 616 620 369  
Suite 401, 55 Flemington Road  
North Melbourne  
Victoria, 3051  
Australia

---

## **Telix and Heidelberg University Hospital to Develop Next Generation Theranostics**

*Melbourne (Australia) and Heidelberg (Germany) – 10<sup>th</sup> February 2021.* Telix Pharmaceuticals Limited (ASX: TLX, 'Telix', the 'Company') today announces it has concluded a research cooperation agreement with Heidelberg University Hospital in Germany (UKHD) to develop next generation theranostic radiopharmaceuticals for urologic oncology.

Under the terms of the agreement, Telix and UKHD will co-develop new conjugates and constructs for diagnostic and therapeutic ('theranostic') use.

The goal of the collaboration is to identify candidates and generate sufficient data to proceed to first in human (FIH) trials, with all candidates being evaluated in a pre-clinical study (in vitro and in vivo analysis, toxicology, and manufacturing suitable for clinical translation).

Telix CEO, Dr. Chris Behrenbruch stated, "We are delighted to announce this research cooperation agreement, which formalises the strengthening relationship between Telix and University Hospital Heidelberg. We could not be more excited by the potential of this collaboration to develop and potentially commercialise new therapeutic products to serve the needs of patients living with cancer."

Prof. Frederik Giesel, Vice Chair of Nuclear Medicine Department at UKHD added, "We are thrilled to dive into a deeper collaboration between Telix and UKHD to devote our expertise in possible new theranostic agents and novel radionuclide combinations to improve patient care in urologic oncology, particularly prostate cancer."

### **About University Hospital Heidelberg**

Heidelberg University is the oldest university in Germany; its first medical lectures were held here in 1388. Today, it is one of the largest and most prestigious medical centres in Europe, with a reputation based on excellent patient care, research, and teaching. Heidelberg University Hospital offers inpatients and outpatients an innovative and effective diagnosis and therapy for all complex diseases. In modern buildings with state-of-the-art equipment, specialized teams of physicians, technicians, engineers, and physicists deliver medical care to the highest international standards. The proximity and interlinking of the specialist departments benefit the patient, with interdisciplinary cooperation ensuring optimal treatment. Jointly with the German Cancer Research Center (DKFZ) and German Cancer Aid, Heidelberg University Hospital has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic. For more information, please visit [www.klinikum.uni-heidelberg.de](http://www.klinikum.uni-heidelberg.de).

### **About Telix Pharmaceuticals Limited**

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit [www.telixpharma.com](http://www.telixpharma.com) and follow us on [Twitter](https://twitter.com/TelixPharma) (@TelixPharma) and [LinkedIn](https://www.linkedin.com/company/telix-pharmaceuticals).

Telix's lead product, Illuccix<sup>®</sup> (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. FDA<sup>1</sup>, and has been granted Priority Review status by the Australian Therapeutic Goods

---

<sup>1</sup> ASX disclosure 24/11/2020.

---

Administration (TGA).<sup>2</sup> Telix is also progressing marketing authorisation applications for Illuccix<sup>®</sup> in the European Union<sup>3</sup> and Canada.<sup>4</sup> None of Telix's products have currently received a marketing authorisation in any jurisdiction.

### **Telix Corporate Contact**

Dr. Christian Behrenbruch  
Telix Pharmaceuticals Limited  
Managing Director and CEO  
Email: [Chris.Behrenbruch@Telixpharma.com](mailto:Chris.Behrenbruch@Telixpharma.com)

### **Telix Investor Relations**

Dr. David N. Cade  
Telix Pharmaceuticals Limited  
CBO and Head of Investor Relations  
Email: [David.Cade@Telixpharma.com](mailto:David.Cade@Telixpharma.com)

### Important Information

*This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "U.S. Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by Dr Christian Behrenbruch, Managing Director and Chief Executive Officer.*

---

<sup>2</sup> ASX disclosure 7/12/2020.

<sup>3</sup> ASX disclosure 1/05/2020.

<sup>4</sup> ASX disclosure 16/12/2020.